Park Medi World targets 5,460 beds by FY28 roadmap

Acquisition: Medicity Hospital, Rudrapur

Park Medi World said it is set to acquire The Medicity Hospital in Rudrapur, Uttarakhand. Management described the asset as a 330-bed multi super speciality hospital. The deal is structured as a 100% stake acquisition in an all-cash transaction valued at about ₹1,770 million. The company indicated the purchase will be funded largely through internal accruals. It also reiterated that debt could be used if required, but the base plan remains internal funding. The acquisition adds to the company’s stated strategy of scaling its North India footprint through a mix of brownfield and inorganic growth. The announcement came alongside a broader roadmap that includes multiple projects under execution across FY26 to FY28.

Deal timeline: two phases through 2030

The company said the transaction will be completed in two phases. It expects to acquire 80% of the stake by 31 August 2026. The remaining 20% stake is expected to be completed by 30 April 2030. This staged structure suggests the company will integrate and operate the hospital while final ownership is fully consolidated later. While the article does not specify regulatory or closing conditions, the dates provide a clear timetable for investors tracking execution. The company did not disclose any contingent consideration or earn-out terms in the details provided. Funding is expected to remain predominantly internal, consistent with the broader capex plan described by management.

What Park Medi World operates today

One company update said the Park Group currently operates 16 hospitals across North India with a combined capacity of 3,960 beds. In a separate earnings-call-related note, the base was referenced at about 3,250 beds, with a plan to reach about 3,910 beds after FY26 additions. Management also stated that with the 330-bed acquisition, the total would reach about 4,290 beds. These disclosures point to different reference points used across communications, such as timing differences or inclusion and exclusion of projects nearing commissioning. What is consistent is that the next phase of growth is bed-led, with multiple facilities either opening or expanding over the next two financial years.

Bed expansion plans: FY26 to FY28 pipeline

The company repeatedly highlighted a large expansion pipeline, with bed additions spread across several cities. One expansion roadmap outlined 660 beds of additions in FY26, comprising Agra (360 beds) and Panchkula (300 beds). The same roadmap indicated FY27 additions of 500 beds (Kanpur 300 and Delhi 200) and FY28 additions of 850 beds (Gorakhpur 400, Ambala Oncology 200, and Rohtak 250). Separately, management commentary also referenced additional projects such as Mohali (150 beds) and an Ambala expansion (200 beds), implying FY28 additions could be presented as 1,000 beds in some disclosures. Management also spoke about a total addition of about 1,500 beds through ongoing projects and, in another instance, about 1,850 beds across FY27 and FY28. Across these variations, the underlying message is that Park Medi World is committing to a multi-city expansion cycle through FY28.

Capacity targets: 5,260, 5,460 and 5,790 mentioned

Different capacity endpoints were cited across updates and management commentary. One note said the company targets bed capacity of about 5,460 by March 2028. Another said the plan is to add 1,500 beds and take capacity to about 5,790 beds by March 2028, from a 3,960-bed base. A separate earnings call summary targeted about 5,260 beds by March 2028. Management also stated that, post acquisition, it would reach 4,290 beds and, with the addition of 1,500 beds over FY26, FY27 and FY28, total capacity would go to about 5,790 beds. For investors, the key takeaway is not the exact single number in isolation, but that the company is guiding to a capacity outcome above 5,000 beds by FY28, supported by multiple projects already named and scheduled.

Capex: guidance, totals and unit economics

Park Medi World’s capex numbers were also disclosed in more than one way. One data point put FY27 capex guidance at about ₹550 million and FY28 capex at about ₹2,500 million. Another update described total capex (FY27 to FY28) at about ₹5,000 million, supported by strong annual operating cash flows of about ₹3,500 million. A separate note cited a planned capex of about ₹7,000 million for expansion by March 2028, with capex per bed maintained at about ₹3.4 to ₹3.5 million. The Panchkula project was highlighted as a benchmark for cost efficiency: a 350-bed greenfield facility at capex of about ₹1,250 million, implying about ₹3.5 million per bed. These figures, where consistent, point to a focus on scaling beds without sharply rising capital intensity.

Funding plan: internal accruals first, debt if required

The company repeatedly said expansion will be funded largely through internal accruals. One update said the company aims to avoid major debt by leveraging annual operating cash flow of about ₹3,500 million and cash reserves of about ₹4,140 million. Management also stated it would use debt if required, but positioned that as a secondary option. This matters because a bed-led buildout can stretch balance sheets if ramp-up is slower than planned. By emphasising internal funding and existing liquidity, the company is framing the expansion as manageable within operating cash generation. The article does not provide updated net debt or leverage ratios, so the funding discussion remains at the level of management intent and disclosed cash flow and cash balance figures.

Mix and profitability targets management cited

Park Medi World said super speciality contributes about 65% of its mix, with an aim to scale this to 70% to 75%. In the expansion commentary, management also flagged margin and return targets: EBITDA margin expected to sustain at about 26% to 27% and PAT margin at about 15% to 17% over the medium to long term. Another note cited a targeted EBITDA margin of 27% and PAT margin of 17%, alongside targeted ROCE of 21% and ROE of 23%. The same expansion roadmap described new hospitals reaching EBITDA breakeven at around 30% occupancy, achieving about 20% margin in year two and normalising to 26% to 27% by year three. These targets are framed as expectations, not audited results, and would depend on occupancy ramp-up and case-mix execution.

Market reaction and revenue expectations mentioned

Following the acquisition announcement, Park Medi World shares rose 7.92% to ₹280, according to the market update. Management also provided revenue expectations in a corporate conversation: FY27 total revenue “to the tune of” about ₹20,800 million and FY28 total revenue of about ₹25,500 million. Separately, a performance snapshot cited Q3 FY26 revenue of ₹4,100 million (up 18% year-on-year) and nine-month revenue of ₹12,189 million (up 17% year-on-year). It also cited Q3 EBITDA of ₹994 million with a 24% margin and nine-month EBITDA of ₹3,170 million with a 26% margin. Q3 PAT was cited at ₹528 million and nine-month PAT at ₹1,968 million, up 40% year-on-year. These numbers provide context on the scale from which the company plans to fund and execute the next phase of growth.

Key facts at a glance

Why this matters for investors tracking hospital expansion

The acquisition adds immediate operating capacity in a region where Park Medi World is already building a cluster presence. A cluster strategy can support doctor hiring, referral flows, procurement efficiencies, and marketing leverage, although the article does not quantify these benefits. The disclosed bed-addition schedules across FY26 to FY28 also create multiple execution checkpoints, from commissioning dates to occupancy ramp-up. Capex-per-bed commentary, especially the Panchkula benchmark of about ₹3.5 million per bed, provides a way to judge whether future projects remain within stated capital intensity. The combination of internal accrual funding, disclosed operating cash flows and stated cash reserves is central to the company’s “growth without major debt” messaging. But the staged acquisition timeline through 2030 also means investors may track how quickly the acquired hospital is integrated and how performance evolves before the final 20% stake is purchased.

What to watch next

The next concrete milestones are the 31 August 2026 date for the initial 80% acquisition and the commissioning and ramp-up of the FY26 and FY27 projects referenced in company notes. Investors will likely monitor whether the company maintains capex discipline near the stated ₹3.4 to ₹3.5 million per bed range as the pipeline advances. Another watchpoint is whether the super speciality share rises from 65% toward the 70% to 75% target as new oncology and tertiary care beds are added. Management has also laid out medium-term margin expectations that are closely tied to occupancy and case mix, making quarterly utilisation and profitability trends important. The company’s next earnings updates and project commissioning announcements should provide clarity on which capacity target, among the various numbers cited, becomes the definitive FY28 endpoint.